The European Medicines Agency (EMA) offers consultations in parallel with the European Network for Health Technology Assessment (EUnetHTA) as of July 2017. This aims to allow medicine developers to obtain feedback from regulators and health technology assessment (HTA) bodies on their evidence-generation plans to support decision-making on marketing authorisation and reimbursement of new medicines at the same time.
View this resource Bookmark this resource
Joint EMA-HTA Scientific Advice
Published by IRDiRC
Regulatory AffairsScientific AdviceEUnetHTAHTA Bodies